| scholarly article | Q13442814 |
| P50 | author | Aurélien Marabelle | Q42303208 |
| P2093 | author name string | Michael R Green | |
| Gang Zhou | |||
| Lawrence Steinman | |||
| Michael D Rosenblum | |||
| Richard Luong | |||
| Joshua Brody | |||
| Robert C Axtell | |||
| Ronald Levy | |||
| Holbrook Kohrt | |||
| Hyam I Levitsky | |||
| Bahareh Ajami | |||
| Idit Sagiv-Barfi | |||
| James Torchia | |||
| Ranjani Rajapaksa | |||
| Victor Tse | |||
| P2860 | cites work | Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 |
| Targeting regulatory T cells in cancer | Q27022348 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Regulatory T cell lineage specification by the forkhead transcription factor foxp3 | Q28510328 | ||
| X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy | Q29619109 | ||
| The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype | Q33754618 | ||
| Trafficking of immune cells in the central nervous system | Q33815795 | ||
| Control of immunity by the TNFR-related molecule OX40 (CD134) | Q33899607 | ||
| In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study | Q34194680 | ||
| Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments | Q34353684 | ||
| Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy | Q46934849 | ||
| The reverse stop-signal model for CTLA4 function | Q48540784 | ||
| Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells. | Q48840845 | ||
| IL-12 is required for anti-OX40-mediated CD4 T cell survival. | Q51967359 | ||
| Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. | Q53545523 | ||
| TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. | Q54440010 | ||
| Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. | Q55475056 | ||
| Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. | Q55475096 | ||
| Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | Q80736139 | ||
| Regulatory T cells in cancer | Q34550248 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. | Q34616628 | ||
| Tregs and rethinking cancer immunotherapy | Q34625147 | ||
| IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 | ||
| FOXP3 defines regulatory T cells in human tumor and autoimmune disease | Q34658386 | ||
| Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. | Q34853757 | ||
| C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. | Q34967101 | ||
| OX40 costimulation turns off Foxp3+ Tregs. | Q36007580 | ||
| Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression | Q36399807 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| Checkpoint blockade in cancer immunotherapy | Q36490768 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| Chemotherapy delivery issues in central nervous system malignancy: a reality check. | Q36835363 | ||
| Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease | Q36911056 | ||
| T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy | Q37157984 | ||
| TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40 | Q37197918 | ||
| Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees | Q37420514 | ||
| Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance | Q37440379 | ||
| T-regulatory cell modulation: the future of cancer immunotherapy? | Q37454346 | ||
| Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system | Q37583027 | ||
| Differences in tumor regulatory T-cell localization and activation status impact patient outcome. | Q37609835 | ||
| Immunological considerations of modern animal models of malignant primary brain tumors. | Q37611109 | ||
| The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications | Q37809158 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Firefly luciferase-based dynamic bioluminescence imaging: a noninvasive technique to assess tumor angiogenesis | Q39725148 | ||
| Mouse 4T1 breast tumor model | Q39989082 | ||
| CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells | Q40266751 | ||
| Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models | Q40666022 | ||
| Cancer immunotherapy--the endgame begins | Q41845460 | ||
| Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis. | Q42747710 | ||
| Successful treatment of melanoma brain metastases with adoptive cell therapy. | Q42933679 | ||
| A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma | Q43293811 | ||
| Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors | Q44882612 | ||
| Phase I/II study of ipilimumab for patients with metastatic melanoma | Q46087025 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2447-2463 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Depleting tumor-specific Tregs at a single site eradicates disseminated tumors | |
| P478 | volume | 123 |
| Q41593116 | "In situ" vaccination for systemic effects in follicular lymphoma |
| Q35863346 | 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice |
| Q50072990 | A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy |
| Q38206719 | A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…. |
| Q56889692 | A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity |
| Q64268074 | A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system |
| Q50538951 | A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. |
| Q36099453 | A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts |
| Q56889868 | APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications |
| Q58785196 | Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide |
| Q35216973 | Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy |
| Q47950137 | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression |
| Q47569046 | Advances in immunotherapeutic research for glioma therapy. |
| Q90482750 | Advances in targeted therapy for malignant lymphoma |
| Q92501379 | Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response |
| Q56892472 | Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy |
| Q45072184 | Anticancer drugs: Cracking the combination |
| Q48112970 | Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking |
| Q50056654 | B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors |
| Q34487689 | Big opportunities for small molecules in immuno-oncology |
| Q88109417 | Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression |
| Q41009948 | Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. |
| Q38440279 | Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. |
| Q89748572 | CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors |
| Q37042256 | CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer |
| Q57462232 | CD8 T-Cell Density Imaging with Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols |
| Q38413093 | CTLA-4 Limits Anti-CD20-Mediated Tumor Regression |
| Q36387028 | Cancer immunotherapy: Strategies for personalization and combinatorial approaches |
| Q50423295 | Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models |
| Q92970937 | Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment |
| Q38636430 | Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. |
| Q38645178 | Combination cancer immunotherapies tailored to the tumour microenvironment |
| Q57138329 | Combination immune checkpoint blockade as an effective therapy for mesothelioma |
| Q38852256 | Combinatorial approach to cancer immunotherapy: strength in numbers |
| Q41863325 | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. |
| Q41205250 | Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells. |
| Q42317483 | CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. |
| Q50863789 | Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. |
| Q36268306 | Current clinical trials testing combinations of immunotherapy and radiation. |
| Q39330984 | Delivering safer immunotherapies for cancer |
| Q35060537 | Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity |
| Q27325140 | Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression |
| Q90317070 | Development and characterization of mammary intraductal (MIND) spontaneous metastasis models for triple-negative breast cancer in syngeneic mice |
| Q64921875 | Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. |
| Q48375822 | Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model |
| Q59809040 | Effects of tumor metabolic microenvironment on regulatory T cells |
| Q28085563 | Engineering New Approaches to Cancer Vaccines |
| Q37114367 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? |
| Q48131172 | Eradication of spontaneous malignancy by local immunotherapy. |
| Q42363054 | Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. |
| Q90811913 | Fonctions de CD28, CTLA-4 et PD-1 |
| Q57118934 | Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells |
| Q90441910 | Harnessing innate immunity in cancer therapy |
| Q34418112 | How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? |
| Q40211555 | Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis |
| Q39680352 | Hydroquinone-induced FOXP3-ADAM17-Lyn-Akt-p21 signaling axis promotes malignant progression of human leukemia U937 cells |
| Q58561264 | Hyperprogressive disease: recognizing a novel pattern to improve patient management |
| Q91691686 | IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development |
| Q35220644 | Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma |
| Q88213457 | Imaging activated T cells predicts response to cancer vaccines |
| Q38806038 | Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers |
| Q54238337 | Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. |
| Q90503462 | Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum? |
| Q38821875 | Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop |
| Q35142851 | Immunomodulatory antibody therapy of cancer: the closer, the better |
| Q93162619 | Improving cancer immunotherapy through nanotechnology |
| Q38727470 | In situ vaccination for the treatment of cancer. |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q26991976 | In-situ tumor vaccination: Bringing the fight to the tumor |
| Q41628716 | Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody |
| Q39017623 | Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? |
| Q41900201 | Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection |
| Q45854947 | Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. |
| Q39043844 | Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally |
| Q37482664 | Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma |
| Q54734909 | Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. |
| Q42922291 | Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity |
| Q42594097 | Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs |
| Q40200990 | Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses |
| Q37691837 | Intratumoral immunization: a new paradigm for cancer therapy |
| Q38518518 | Intratumoral immunotherapy for melanoma |
| Q34457797 | Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab |
| Q64082651 | Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q34545316 | Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. |
| Q41830647 | Local immunomodulation for cancer therapy: Providing treatment where needed |
| Q33933665 | Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy |
| Q38986891 | Naive tumour-specific CD4+ T cells were efficiently primed in acute lymphoblastic leukaemia. |
| Q42707140 | Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q35300077 | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape |
| Q43103686 | New insights into the mechanism of action of immune checkpoint antibodies |
| Q94552595 | New pathways in immune stimulation: targeting OX40 |
| Q38974085 | Nutrients and the microenvironment to feed a T cell army |
| Q38374889 | OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. |
| Q90292123 | OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers |
| Q44805706 | OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy |
| Q37180457 | OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential. |
| Q90598729 | Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies |
| Q38848223 | Oncolytic Immunotherapy for Treatment of Cancer |
| Q38262255 | Overcoming tumor-mediated immunosuppression |
| Q90135121 | PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity |
| Q38358045 | Paradigm shift in oncology: targeting the immune system rather than cancer cells |
| Q38690773 | Pattern recognition receptors: immune targets to enhance cancer immunotherapy |
| Q35607012 | Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response |
| Q50545420 | Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis. |
| Q36664213 | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer |
| Q91584518 | Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer |
| Q30360210 | Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. |
| Q46264331 | Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model |
| Q38174058 | Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. |
| Q27310763 | Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q36673061 | Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis |
| Q47122059 | STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC. |
| Q34391446 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial |
| Q30638240 | Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine |
| Q36755491 | Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia |
| Q38841677 | Strategies for designing synthetic immune agonists |
| Q36827406 | Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models |
| Q42727084 | T cell responses: naive to memory and everything in between |
| Q21131200 | TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu |
| Q37706972 | TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo |
| Q64934973 | TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. |
| Q45064262 | TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines |
| Q38323786 | Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. |
| Q89388664 | Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma |
| Q36890918 | Targeting immunosuppression for cancer therapy |
| Q64102267 | Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB |
| Q38271877 | Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? |
| Q35176307 | Targeting the tumor microenvironment to enhance antitumor immune responses |
| Q38805897 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy |
| Q36207348 | Targeting the tumor niche to treat cancer |
| Q33736218 | The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment |
| Q47162933 | The Future of Immunotherapy: A 20-Year Perspective |
| Q38811689 | The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice |
| Q38209978 | The early history of Stanford Immunology |
| Q35060384 | The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 |
| Q38216836 | The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. |
| Q38534294 | The importance of the tumor microenvironment in the therapeutic management of cancer |
| Q90003208 | The multifaceted immune regulation of bladder cancer |
| Q37181696 | The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade |
| Q58924840 | The swinging pendulum of cancer immunotherapy personalization |
| Q50266733 | Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. |
| Q37690485 | Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy |
| Q57295884 | Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity |
| Q55268648 | Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. |
| Q40473497 | Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. |
| Q26996518 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications |
| Q90737393 | Tumor Targeted Nanocarriers for Immunotherapy |
| Q38974641 | Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation |
| Q50930285 | Tumour immunology: cracking the combination. |
| Q26863525 | Ubiquitin-dependent regulation of Foxp3 and Treg function |
| Q42261548 | Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer |
| Q28067648 | Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together |
| Q49958115 | Using immunotherapy to boost the abscopal effect |
| Q39043404 | Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update |
Search more.